Jan Willem B de Groot
Overview
Explore the profile of Jan Willem B de Groot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
2642
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma
de Groot S, Blommestein H, Leeneman B, Uyl-de Groot C, Haanen J, Wouters M, et al.
Med Decis Making
. 2025 Feb;
:272989X251319338.
PMID: 39985400
Background: A decision model for patients with advanced melanoma to estimate outcomes of a wide range of treatment sequences is lacking. Objectives: To develop a decision model for advanced melanoma...
2.
Blommestein H, de Groot S, Leeneman B, Uyl-de Groot C, Haanen J, Wouters M, et al.
Eur J Cancer
. 2025 Feb;
218:115071.
PMID: 39914026
Background: This study aims to evaluate the cost-effectiveness of treatment sequences for patients with advanced melanoma with a BRAF mutation in the Netherlands from a societal perspective. Methods: A semi-Markov...
3.
Schadendorf D, Dummer R, Flaherty K, Robert C, Arance A, de Groot J, et al.
Future Oncol
. 2025 Jan;
21(5):523-531.
PMID: 39810544
No abstract available.
4.
Bond M, Bolhuis K, Loosveld O, de Groot J, Droogendijk H, Helgason H, et al.
JAMA Oncol
. 2024 Nov;
11(1):36-45.
PMID: 39570583
Importance: In patients with colorectal cancer and unresectable liver-only metastases (CRLM), treatment with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) plus irinotecan (FOLFOXIRI) and bevacizumab vs FOLFOX/folinic acid, fluorouracil, and irinotecan...
5.
Rauwerdink D, Not O, de Meza M, van Doorn R, Hage J, van den Eertwegh A, et al.
Cancers (Basel)
. 2024 Aug;
16(15).
PMID: 39123384
: The difference in incidence and severity of anti-PD-1 therapy-related adverse events (irAEs) between adjuvant and advanced treated melanoma patients remains unclear, as no head-to-head studies have compared these groups....
6.
Thomassen B, Kimman M, Somers A, Ponds R, Dekker J, van Leiden B, et al.
Eur J Surg Oncol
. 2024 Jul;
:108552.
PMID: 39074994
No abstract available.
7.
Van Duin I, Schuiveling M, Ter Maat L, Van Amsterdam W, van den Berkmortel F, Boers-Sonderen M, et al.
Eur J Cancer
. 2024 Jul;
208:114190.
PMID: 38991284
Introduction: The presence of tumor-infiltrating lymphocytes (TILs) in melanoma has been linked to survival. Their predictive capability for immune checkpoint inhibition (ICI) response remains uncertain. Therefore, we investigated the association...
8.
Leek L, Notohardjo J, de Joode K, Velker E, Haanen J, Suijkerbuijk K, et al.
Sci Rep
. 2024 May;
14(1):11244.
PMID: 38755213
We evaluated the prognostic value of hypoalbuminemia in context of various biomarkers at baseline, including clinical, genomic, transcriptomic, and blood-based markers, in patients with metastatic melanoma treated with anti-PD-1 monotherapy...
9.
Schadendorf D, Dummer R, Flaherty K, Robert C, Arance A, de Groot J, et al.
Eur J Cancer
. 2024 May;
204:114073.
PMID: 38723373
Background: Treatment with encorafenib plus binimetinib and encorafenib monotherapy is associated with improved progression-free survival (PFS) and overall survival (OS) compared with vemurafenib in patients with BRAF V600E/K-mutant metastatic melanoma....
10.
Filipe W, Buisman F, Franssen S, Krul M, Grunhagen D, Bennink R, et al.
HPB (Oxford)
. 2024 Apr;
26(7):919-927.
PMID: 38604828
Introduction: This study investigates the incidence of extrahepatic perfusion and incomplete hepatic perfusion at intraoperative methylene blue testing and on postoperative nuclear imaging in patients undergoing hepatic arterial infusion pump...